STOK Stoke Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: STOK

Price (delayed)

$12.02

Market cap

$556.57M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.38

Enterprise value

$364.56M

Stoke Therapeutics, is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the company's proprietary TANGO (Targeted Augmentation of ...

Highlights
The EPS has grown by 8% YoY
The company's gross profit fell by 29% YoY and by 5% QoQ
The revenue has contracted by 29% YoY and by 5% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.stoketherapeutics.com
Peers: OMER OMGA

Key stats

What are the main financial stats of STOK
Market
Shares outstanding
46.3M
Market cap
$556.57M
Enterprise value
$364.56M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.36
Price to sales (P/S)
60.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
41.52
Earnings
Revenue
$8.78M
EBIT
-$114.61M
EBITDA
-$109.88M
Free cash flow
-$82.68M
Per share
EPS
-$2.38
Free cash flow per share
-$1.88
Book value per share
$3.57
Revenue per share
$0.2
TBVPS
$5.19
Balance sheet
Total assets
$228.34M
Total liabilities
$68.78M
Debt
$0
Equity
$159.57M
Working capital
$184.52M
Liquidity
Debt to equity
0
Current ratio
6.99
Quick ratio
6.55
Net debt/EBITDA
1.75
Margins
EBITDA margin
-1,251.5%
Gross margin
100%
Net margin
-1,192.5%
Operating margin
-1,307.2%
Efficiency
Return on assets
-41.6%
Return on equity
-56.9%
Return on invested capital
-348.7%
Return on capital employed
-58%
Return on sales
-1,305.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

STOK stock price

How has the Stoke Therapeutics stock price performed over time
Intraday
2.82%
1 week
-3.14%
1 month
-6.2%
1 year
26.66%
YTD
128.52%
QTD
-10.96%

Financial performance

How have Stoke Therapeutics's revenue and profit performed over time
Revenue
$8.78M
Gross profit
$8.78M
Operating income
-$114.77M
Net income
-$104.7M
Gross margin
100%
Net margin
-1,192.5%
The operating margin has plunged by 55% YoY and by 8% from the previous quarter
STOK's net margin is down by 46% year-on-year and by 7% since the previous quarter
The company's gross profit fell by 29% YoY and by 5% QoQ
The revenue has contracted by 29% YoY and by 5% from the previous quarter

Growth

What is Stoke Therapeutics's growth rate over time

Valuation

What is Stoke Therapeutics stock price valuation
P/E
N/A
P/B
3.36
P/S
60.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
41.52
The EPS has grown by 8% YoY
The P/B is 98% above the last 4 quarters average of 1.7 but 4% below the 5-year quarterly average of 3.5
Stoke Therapeutics's equity has decreased by 14% YoY and by 8% from the previous quarter
The price to sales (P/S) is 96% higher than the last 4 quarters average of 30.7
The revenue has contracted by 29% YoY and by 5% from the previous quarter

Efficiency

How efficient is Stoke Therapeutics business performance
STOK's return on invested capital has dropped by 84% since the previous quarter
The ROS has plunged by 55% YoY and by 8% from the previous quarter
The ROE has declined by 20% year-on-year and by 4.8% since the previous quarter
STOK's ROA is down by 19% YoY and by 4% from the previous quarter

Dividends

What is STOK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for STOK.

Financial health

How did Stoke Therapeutics financials performed over time
STOK's current ratio is down by 23% since the previous quarter and by 10% year-on-year
Stoke Therapeutics's quick ratio has decreased by 23% from the previous quarter and by 11% YoY
STOK's debt is 100% smaller than its equity
Stoke Therapeutics's equity has decreased by 14% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.